Author | Robert P. Huben, MD


Commentary (Huben): Management of Asymptomatic Rising PSA After Prostatectomy or Radiation Therapy

April 01, 1997

As the number of cases of newly diagnosed prostate cancer has risen dramatically in the United States during the past decade, the management of a rising prostate-specific antigen (PSA) level following definitive therapy has become an increasingly common dilemma. Waxman and associates provide a concise, focused review of many of the key issues and controversies surrounding this dilemma. Several of these issues warrant particular attention.